Antibody-based cancer therapies have become a cornerstone of modern oncology, offering targeted and highly specific treatment options. These therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, target tumor antigens or modulate immune responses. Their efficacy in controlling and eliminating various cancer types is remarkable; however, optimizing these treatments necessitates robust, reproducible, and innovative methodologies. 

This Methods Collection aims to provide a comprehensive overview of in vitro, ex vivo, and in vivo approaches for assessing anti-cancer antibody-based therapeutics. In vitro techniques may include binding affinity assays, antibody-dependent cellular cytotoxicity (ADCC) studies, and mechanistic investigations using tumour and immune cell lines. Ex vivo methods may explore patient-derived organoids, tumor explants, and co-culture systems for personalized drug response analysis. In vivo models, including genetically engineered mice, humanized mice, and xenografts, will support preclinical evaluations of drug pharmacokinetics, safety, and anti-tumor effects. 

The Collection encourages, but is not limited to, submissions addressing challenges in evaluating therapeutic performance within the tumor microenvironment, reducing off-target effects, and testing the efficacy of combination therapies.